OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2021
(3)
2025
(2)
2024
(2)
2023
(1)
2015
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Sudden unexpected postnatal collapse and BUB1B mutation: first forensic case report.
Not available
S-EPMC11306263
|
biostudies-literature
Cite
Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.
Not available
S-EPMC12584038
|
biostudies-literature
Cite
Unbalanced Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinases Ratios Predict Hemorrhagic Transformation of Lesion in Ischemic Stroke Patients Treated with Thrombolysis: Results from the MAGIC Study.
Not available
S-EPMC4445323
|
biostudies-literature
Cite
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
Not available
S-EPMC8047485
|
biostudies-literature
Cite
Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030.
Not available
S-EPMC11321301
|
biostudies-literature
Cite
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study.
Not available
S-EPMC7980742
|
biostudies-literature
Cite
Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa-Carbidopa Intestinal Gel: A Nation-Wide, Multicenter, Longitudinal, "Real-World" Study. The EPIC Study.
Not available
S-EPMC12260476
|
biostudies-literature
Cite
Progressive myoclonus epilepsies-Residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes.
Not available
S-EPMC8059372
|
biostudies-literature
Cite
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Not available
S-EPMC10070417
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets